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Abstract
Background Activation of receptor for advanced glyca-
tion end products (RAGE) leads to the proinflammatory
response and the release of its soluble form (sRAGE)
which appears to function as an anti-inflammatory feed-
back mechanism.
Aim To determine serum sRAGE concentration in CSU
patients and its association with C-reactive protein (CRP)
concentration, a nonspecific inflammatory marker of the
disease activity.
Methods Concentrations of sRAGE and CRP were mea-
sured in serum of CSU patients and compared with the
healthy controls.
Results Serum sRAGE concentrations were significantly
decreased in CSU patients, especially those more severely
affected. In addition, significant inverse correlations were
observed between sRAGE and CRP concentrations.
Conclusions Down-regulation of sRAGE and its associ-
ation with acute phase response suggest a role for RAGE
activation in the pathogenesis of CSU. It seems that lower
serum sRAGE concentration may enhance the urticarial
processes.
Keywords Soluble receptor for advanced glycation
end products  Chronic spontaneous urticaria 
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Introduction
The pathogenesis of chronic spontaneous urticaria (CSU) is
complex and involves a number of mediators [1–4].
The receptor for advanced glycation end products (RAGE)
is a member of the immunoglobulin superfamily of cell sur-
face molecules, playing an important role in immune/
inflammatory disorders [5–9]. This multiligand receptor binds
a variety of molecules, including advanced glycation end
products (AGEs), amyloid fibrils, S100/calgranulins and
amphoterin, which lead to the inflammatory response and
cellular dysfunction. It is able to increase vascular perme-
ability and recruit leukocytes into sites of inflammation [9,
10]. The soluble form of RAGE (sRAGE) prevents the
receptor-mediated signaling by neutralization/removal of the
proinflammatory ligands, acting as a decoy receptor [7, 11].
Circulating sRAGE has been found to be decreased in
chronic inflammatory diseases [12].
In our previous study, we observed lower AEGs con-
centration in serum of CSU patients, despite the enhanced
systemic inflammatory response. Paradoxical decrease of
serum AGEs concentrations is probably a reflection of
lower concentration of the ‘negative acute phase proteins’,
such as albumin [13]. It seems interesting to perform fur-
ther investigations of the RAGE signaling system in the
disease. Thus, the aim of this study was to determine serum
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sRAGE concentration in CSU patients and its association
with C-reactive protein (CRP) concentration, a nonspecific
inflammatory marker of the disease activity.
Materials and methods
37 patients with active CSU (26 women and 11 men; mean age:
39 ± 9.5 years) with a median disease duration of 2.9 years
were enrolled in the study, as described previously [13].
In all cases, any known causes of CSU were ruled in (out) by
appropriate investigations. Each patient underwent the fol-
lowing tests: routine laboratory tests (FBC, urine analysis,
ESR, C-reactive protein, serum glucose, hepatic functions, and
creatinine), stool (for parasites), hepatitis serology, antinuclear
and antithyroid microsomal antibodies, thyroid function tests,
chest X-ray and abdominal ultrasonography. Additionally,
dental, gynecological and ENT consultations as well as the
autologous serum skin test (ASST) [14] were performed.
The urticaria activity score (UAS) was estimated during
4 days and on the blood sampling day to be graded as
follows: mild (0–8), moderate (9–16) and severe (17–24).
The study comprised 20 patients with mild and 17 patients
with moderate-severe urticaria symptoms.
None of the examined subjects had taken any oral cor-
ticosteroids within 5 weeks or antihistamines within at
least 5 days before the study.
The control group consisted of 24 healthy individuals
(13 women and 11 men), of comparable age
(41.3 ± 8.2 years) and BMI (\30).
The Ethics Committee of the Medical University of
Silesia approved of the study and written, informed consent
was obtained from all the subjects participating.
RAGE concentration assay
sRAGE in tested serum samples were determined using
Human RAGE/AGER ELISA Kit (Sigma-Aldrich, Saint
Louis, MO) according to manufacturers’ recommendations.
Absorbances were read with the Power Wave XS plate
reader (BioTek, Winooski, VT) at 450 nm (reference wave
length -630 nm), and results processed with the KC Junior
software (BioTek, Winooski, VT).
Determinations were done during one series. The intra-
assay variation was 8 %. The assay sensitivity was 3 pg/ml.
Assay of CRP concentration
Serum C-reactive protein (CRP) concentrations were
assayed using Roche/Hitachi cobas c system. Normal lab
ranges: lower than 5.0 mg/l.
Autologous serum skin test (ASST)
Intradermal ASST was performed following the method by
Sabroe et al. [14]. Serum-induced a red wheal response of
diameter greater by at least 1.5 mm than that of the control
wheal, induced by physiological saline, was accepted as
positive. Skin prick test with histamine served as a positive
control.
Statistical analysis
The obtained results were presented using basic parameters
of descriptive statistics, such as median value, quartile
range, mean value and standard deviation. Normal distri-
bution of data was measured using Shapiro–Wilk’s test.
Independent data between the groups of patients with CSU
and the control group and between CSU patients with mild
and moderate-severe symptoms were compared using non-
parametric U Mann–Whitney test. The Spearman’s rank
test was used for correlations. The values of p\ 0.05 were
considered statistically significant. Calculations were per-
formed with STATISTICA for Windows 10.0 software
(StatSoft, Cracow, Poland).
Serum sRAGE concentration
Serum concentration of sRAGE was significantly lower in
CSU patients as compared with the healthy subjects (me-
dian 551.4 vs. 1037.25 pg/ml; p\ 0.00001; Fig. 1).
sRAGE serum concentration was significantly lower in
moderate-severe CSU patients as compared with those with
mild CSU and the healthy subjects (median 362.99 vs.
663.85 vs. 1037.25 pg/ml, p\ 0.00001 and p\ 0.01,
respectively). In addition, sRAGE concentration in mild
CSU patients was significantly lower than in the health
subject (663.85 vs. 1037.25 pg/ml, p\ 0.001).
No significant differences in sRAGE concentrations
between ASST(?) and ASST(-) CSU patients (selected
according to the similar UAS) were observed.
Serum CRP concentration
Serum CRP concentrations were significantly higher in
CSU patients as compared with the healthy subjects (me-
dian 2.85 vs. 1.02 mg/l, p\ 0.00001). CRP concentration
in moderate-severe CSU group was significantly higher
than in mild CSU group and the healthy subjects (median
10.30 vs. 1.2 vs. 1.02 mg/l, p\ 0.00001). There was no
significant difference in serum CRP concentration between
patients with mild CSU and the control group (median 1.2
vs. 1.02 mg/l, p = 0.07) [13].
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Associations
There was a significant negative correlation between
sRAGE and CRP concentrations in CSU patients
(R = -0.35, p = 0.03), but not in the healthy subjects
(R = 0.24, p = 0.26). There were no significant correla-
tions between sRAGE and AGEs [13] concentrations,
neither in CSU patients (R = -0.13, p = 0.44) nor in the
healthy controls (R = 0.29, p = 0.12).
Discussion
To the best of our knowledge, this study is the first to
demonstrate any association between serum sRAGE con-
centrations and the urticarial processes.
We provide evidence that serum sRAGE concentration
is decreased in CSU patients as compared with the healthy
subjects, and it is inversely associated with CRP—a marker
of CSU activity and the inflammatory response [2, 3].
These data suggest that such lowers sRAGE concentration
in CSU patients could be considered as a reflection of their
inflammatory status.
Nevertheless, the mechanism and clinical significance of
decreased circulating sRAGE concentrations in CSU are
currently unclear.
Theoretically, lower sRAGE concentrations in CSU
patients can be explained by different mechanisms. It
seems likely that similarly to other diseases, associated
with the systemic inflammatory response, there is a wide
diversity of RAGE ligands in the inflamed skin and/or in
the circulation, that could bind and eliminate sRAGE,
leading to lower circulating concentrations of sRAGE in
CSU [10, 11]. Another intriguing possibility is that, either
primary or secondary dysregulation of RAGE system leads
to insufficient sRAGE production in CSU.
The role for circulating sRAGE in CSU is currently
unknown.
It is known, that sRAGE regulates RAGE-mediated
processes by contributing to the removal/neutralization of
circulating ligands and appears to function as an anti-in-
flammatory feedback mechanism [11, 15]. In addition, it
has been demonstrated that decreased sRAGE concentra-
tions is associated with the increased inflammation in
various disorders [12, 16]. On the other hand, higher
plasma concentration of sRAGE reduces the risk of
inflammatory complications in several chronic diseases [7,
11]. Consequently, one might speculate, that decreased
concentration of sRAGE in CSU may increase the
propensity towards inflammation by facilitating RAGE-
dependent cellular activation and proinflammatory
response, similarly to other diseases/conditions [5, 6, 9,
12].
So far, it has only been our previous study to focus on
the involvement of the AGEs–RAGE axis in CSU. We
found that CSU patients had significantly decreased serum
AGEs concentrations, as compared with the healthy sub-
jects [13]. However, serum sRAGE concentrations were
found not to correlate with circulating AGEs concentra-
tions, suggesting interactions with other proinflammatory
ligands, including amyloid fibrils, S100/calgranulins and
amphoterin.
Fig. 1 Serum RAGE
concentration in the healthy
subjects and chronic
spontaneous urticaria (CSU)
patients with different disease
activity. CSU (all) versus
controls, p\ 0.00001;
moderate-severe CSU versus
mild CSU versus controls,
p\ 0.00001 and p\ 0.01,
respectively; mild CSU versus
controls, p\ 0.001
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In the present study, serum sRAGE concentration was
significantly lower in moderate-severe CSU patients, as
compared with those with mild CSU and the healthy sub-
jects. In addition, sRAGE concentration in mild CSU
patients was significantly lower than in the healthy
subjects.
However, as serum sRAGE concentrations were not
compared between moderate and severe CSU patients, and
because of a relatively small study group, further research
is necessary to address the issues of precise relation
between circulating sRAGE and the disease
activity/severity.
Conclusions
Serum sRAGE concentrations were significantly decreased
in CSU patients, especially those more severely affected,
and were inversely related to CRP, a nonspecific inflam-
matory marker of the disease activity. Down-regulation of
sRAGE and its association with the acute phase response
suggest a role for RAGE activation in the pathogenesis of
CSU. It seems that lower serum sRAGE concentration may
enhance the urticarial processes.
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